Risk Prediction Models and Scores in Hypertrophic Cardiomyopathy

Author(s): Thomas D. Gossios*, Konstantinos Savvatis, Thomas Zegkos, Despina Parcharidou, Haralambos I. Karvounis, Georgios K. Efthimiadis

Journal Name: Current Pharmaceutical Design

Volume 27 , Issue 10 , 2021

Become EABM
Become Reviewer
Call for Editor


Hypertrophic cardiomyopathy (HCM) has historically been linked with sudden cardiac death (SCD). Currently, it is well established that only a subset of patients is at the highest risk stratum for such a catastrophic event. Detection of patients belonging to this high-risk category can allow for timely defibrillator implantation, changing the natural history of HCM. Inversely, device implantation in patients deemed at low risk leads to an unnecessary burden of device complications with no apparent protective benefit. Previous studies have identified a series of markers, now considered established risk factors, with genetic testing and newer imaging allowing for the detection of novel, highly promising indices of increased risk for SCD. Despite the identification of a number of risk factors, there is noticeable discrepancy in the utility of such factors for risk stratification between the current American and European guidelines. We sought to systematically review the data available on these two approaches, presenting their rationale and respective predictive capacity, also discussing the potential of novel markers to augment the precision of currently used risk stratification models for SCD in HCM.

Keywords: Hypertrophic cardiomyopathy, sudden death, risk, risk prediction, implantable cardioverter defibrillator, personalized medicine.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2021
Published on: 26 April, 2021
Page: [1254 - 1265]
Pages: 12
DOI: 10.2174/1381612827666210125121115
Price: $65

Article Metrics

PDF: 471